Advanced Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 9, 2025
Abstract
Glioblastoma
(GBM)
remains
one
of
the
deadliest
forms
cancer
due
to
its
high
rates
postoperative
recurrence
and
resistance
treatment.
Temozolomide
(TMZ)
is
standard
chemotherapy
for
GBM.
However,
therapeutic
efficacy
TMZ
significantly
compromised
by
activation
various
intracellular
DNA
repair
mechanisms
that
facilitate
resistance.
Herein,
upregulation
bromodomain‐containing
protein
4
(BRD4)
expression
demonstrated
be
a
key
contributor
in
To
address
this
challenge,
biomimetic
hybrid
PROteolysis
TArgeting
Chimeras
(PROTAC)
liposome
delivery
system
(M@TP)
developed.
This
efficiently
penetrates
blood‐brain
barrier
(BBB)
specifically
targets
GBM
cells
through
homotypic
recognition.
Once
within
TMZ‐resistant
cells,
released
PROTAC
from
M@TP
can
degrade
BRD4,
effectively
inhibiting
multiple
pathways
restoring
sensitivity
In
vivo,
studies
showed
significant
suppressing
tumor
growth
both
GBM,
with
prolonged
mouse
survival
times.
These
findings
highlight
potential
as
promising
strategy
overcome
improve
outcomes
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 24, 2025
Abstract
Glioblastoma
multiforme
(GBM)
is
a
highly
aggressive
and
malignant
brain
tumor
originating
from
glial
cells,
characterized
by
high
recurrence
rates
poor
patient
prognosis.
The
heterogeneity
complex
biology
of
GBM,
coupled
with
the
protective
nature
blood–brain
barrier
(BBB),
significantly
limit
efficacy
traditional
therapies.
rapid
development
nanoenzyme
technology
presents
promising
therapeutic
paradigm
for
rational
targeted
treatment
GBM.
In
this
review,
underlying
mechanisms
GBM
pathogenesis
are
comprehensively
discussed,
emphasizing
impact
BBB
on
strategies.
Recent
advances
in
nanoenzyme‐based
approaches
therapy
explored,
highlighting
how
these
nanoenzymes
enhance
various
modalities
through
their
multifunctional
capabilities
potential
precise
drug
delivery.
Finally,
challenges
prospects
translating
laboratory
research
to
clinical
application,
including
issues
stability,
targeting
efficiency,
safety,
regulatory
hurdles
critically
analyzed.
By
providing
thorough
understanding
both
opportunities
obstacles
associated
therapies,
future
directions
aimed
be
informed
contribute
more
effective
treatments
Advanced Functional Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 18, 2025
Abstract
Nanomedicine
based
brain
targeting
strategies
have
emerged
as
a
promising
avenue
for
ischemic
stroke
(IS)
treatment.
However,
conventional
approaches
face
significant
challenges
in
manipulating
biodistribution
and
achieving
efficient
to
attain
adequate
therapeutic
effects.
Here,
this
limitation
is
overcame
by
developing
magnetic
field
driven,
mitochondria‐targeted
ceria
nanosystem
(MMTCe)
nanosystem.
By
anchoring
nanoparticles
the
cell
membrane,
targeted
delivery
of
achieved
through
use
an
external
field,
which
turn
targets
damaged
mitochondria
repairs
microenvironment.
MMTCe
exhibits
superior
accumulation
within
vitro
blood
barrier
(BBB)
model
rat
stroke.
This
mediates
mitochondrial
function,
thereby
inhibiting
oxidative
stress
aberrant
activation
microglial
cells,
ultimately
inducing
rebalancing
Complemented
favorable
biosafety
profile,
top‐down
fabrication
provides
general
strategy
diseases
informs
development
magnetically
driven
systems.
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 25, 2025
Central
nervous
system
(CNS)
disorders
confront
significant
challenges
in
drug
delivery
due
to
the
blood-brain
barrier
(BBB).
Inspired
by
rapid
and
precise
binding
of
odor
molecules
olfactory
receptors
(ORs),
this
research
uses
thiolated
HPMA
construct
nanoparticles
(nanoodors)
capable
delivering
drugs
CNS
via
olfacto-cerebral
pathway
overcome
obstruction.
The
nanoodor
core
is
used
encapsulate
agomelatine
(AGO),
a
CNS-targeting
antidepressant,
encapsulation
efficiency
exceeded
80%.
A
series
thiol-presenting
nanoscale
structures
with
different
surface
densities
thiol
groups
are
constructed,
effectiveness
positively
correlated
density
on
their
surface.
Notably,
nanoodors
enable
brain-targeted
delivery,
outperforming
commercially
available
oral
formulations
terms
accumulation
brain
antidepressant
effects.
study
transport
action
mechanisms
revealed
that
after
ORs,
rapidly
delivered
pathway.
Nanoodors,
first
design
deliver
mimicking
natural
smells
for
treatment
disorders,
expected
achieve
clinical
transformation,
benefiting
human
health.
Biomedical Technology,
Journal Year:
2024,
Volume and Issue:
7, P. 32 - 45
Published: July 16, 2024
Ischemic
stroke
(IS),
a
major
cause
of
death
and
disability
globally,
requires
innovative
therapeutic
approaches
due
to
its
complex
pathology.
Nature
medicine
(NM)
offers
promising
treatments
through
bioactive
compounds,
which
target
the
multifaceted
nature
stroke-induced
damage.
However,
clinical
application
NM
is
limited
by
challenges
in
bioavailability
specificity.
This
review
article
presents
an
advanced
perspective
on
integrating
nanotechnology
with
create
potent
nanodelivery
systems
for
ischemic
treatment.
We
highlight
pathological
underpinnings
stroke,
including
oxidative
stress,
inflammation,
apoptosis,
discuss
how
compounds
offer
targeted
mitigation
strategies.
By
incorporating
platforms,
such
as
liposomes
nanoparticles,
these
-based
can
achieve
enhanced
targeting,
solubility,
controlled
release,
significantly
improving
outcomes
while
reducing
side
effects.
Despite
developments,
translation
nano-enhanced
into
practice
faces
obstacles,
manufacturing
scalability,
regulatory
approval,
safety
evaluations.
emphasizes
potential
combining
advance
therapy,
calling
integrated
research
efforts
overcome
existing
barriers
fully
realize
benefits
this
approach.
International Journal of Nanomedicine,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 9175 - 9193
Published: Sept. 1, 2024
Ischemic
stroke
is
a
refractory
disease
wherein
the
reperfusion
injury
caused
by
sudden
restoration
of
blood
supply
main
cause
increased
mortality
and
disability.
However,
current
therapeutic
strategies
for
inflammatory
response
induced
cerebral
ischemia-reperfusion
(I/R)
are
unsatisfactory.
This
study
aimed
to
develop
functional
nanoparticle
(MM/ANPs)
comprising
apelin-13
(APNs)
encapsulated
in
macrophage
membranes
(MM)
modified
with
distearoyl
phosphatidylethanolamine-polyethylene
glycol-RVG29
(DSPE-PEG-RVG29)
achieve
targeted
therapy
against
ischemic
stroke.
